Linda G. W. Kerkmeijer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Linda G. W. Kerkmeijer has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Uulke A. van der Heide
Department of radiation oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
7 shared publications - Karin Haustermans
Department of Oncology, KU Leuven, Leuven, Belgium; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium
6 shared publications - Cédric Draulans
Department of Oncology, KU Leuven, Leuven, Belgium; Department of Radiation Oncology, AZ Sint-Maarten Hospital, Mechelen, Belgium
5 shared publications - Robert Jan Smeenk
Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
5 shared publications - Floris J. Pos
Department of Radiation Oncology, The Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands
4 shared publications - Evelyn M. Monninkhof
Julius Center for Health Sciences and Primary care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
3 shared publications
Latest Publications
- 29 April 2024
- Published by Elsevier in The Lancet Oncology
- Vol. 25 (5) , e193-e204
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology
- 29 April 2024
- Published by Elsevier in The Lancet Oncology
- Vol. 25 (5) , e193-e204
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology
- Open Access
- 7 February 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 46, 100742
MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study
- 7 February 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 46, 100742
Open AccessMRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study
- Open Access
- 10 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 186, 109803
Recommendations for improved reproducibility of ADC derivation on behalf of the Elekta MRI-linac consortium image analysis working group
- 10 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 186, 109803
Open AccessRecommendations for improved reproducibility of ADC derivation on behalf of the Elekta MRI-linac consortium image analysis working group
- Open Access
- 1 February 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 167, 127-132
Urethral and bladder dose–effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial
- 1 February 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 167, 127-132
Open AccessUrethral and bladder dose–effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial
- 11 January 2022
- Published by Elsevier in European Urology
- Vol. 82 (2) , 149-151
Magnetic Resonance Imaging–guided Adaptive Radiotherapy for Urological Cancers: What Urologists Should Know
- 11 January 2022
- Published by Elsevier in European Urology
- Vol. 82 (2) , 149-151
Magnetic Resonance Imaging–guided Adaptive Radiotherapy for Urological Cancers: What Urologists Should Know
- 20 September 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (27) , 3086-3087
Reply to I. R. Vogelius et al
- 20 September 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (27) , 3086-3087
Reply to I. R. Vogelius et al
- 1 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S671
642TiP Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer
- 1 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S671
642TiP Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer
- Open Access
- 1 September 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 162, 98-104
Anorectal dose–effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial
- 1 September 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 162, 98-104
Open AccessAnorectal dose–effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial
- Open Access
- 30 August 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Editorial: Online Adaptive MR-Guided Radiotherapy
Editorial: Online Adaptive MR-Guided Radiotherapy
- 30 August 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessEditorial: Online Adaptive MR-Guided Radiotherapy
Editorial: Online Adaptive MR-Guided Radiotherapy